Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;7(11):1350–1373. doi: 10.1038/s41551-023-01061-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, Schematic of the experimental protocol to analyse the effects of AAV-mediated transduction of RVLM astrocytes or neurons with the Agtrap gene. ITR, inverted terminal repeat. b,c, Astrocyte-specific (b) and neuron-specific (c) transgene expression by RVLM injection of AAV9 vectors. Micrographic images of GFP (green) and anti-GFAP (b) or anti-NeuN (c) immunostaining (blue) of RVLM in SHRSPs 15 days after the injection of the AAV9 vectors indicated at the top. Scale bars, 50 μm. Images are representative of three rats. d–f, MAP values just before (day 1) (d) and 2 weeks after (day 15) (e) AAV injection into the RVLM (P = 0.0222 (GFAP-control versus GFAP-AGTRAP) and P > 0.9999 (NSE-control versus NSE-AGTRAP) (d); P = 0.0229 (column 1 versus 2), P = 0.6864 (column 3 versus 4) (e); n = 6 (GFAP-control), n = 7 (GFAP-AGTRAP), n = 7 (NSE-control) and n = 6 (NSE-AGTRAP) rats) and 24 h urinary noradrenaline excretion (f) (P = 0.0497 (column 1 versus 2), P = 0.7455 (column 3 versus 4); n = 4 rats for each group) in SHRSPs after RVLM injection of AAV9 vectors. Data are mean ± s.e.m. Statistical analysis was performed using two-way repeated-measures ANOVA with Bonferroni’s post hoc multiple-comparison test (d) or one-way ANOVA with Tukey’s post hoc multiple-comparison test (e and f); *P < 0.05.

Source data